Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMDGet Rating) in a report published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research upgraded Galmed Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, February 1st.

NASDAQ GLMD opened at $1.57 on Monday. The firm has a market cap of $39.38 million, a PE ratio of -1.05 and a beta of 1.95. Galmed Pharmaceuticals has a one year low of $1.19 and a one year high of $4.08. The stock’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $2.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.88 and a quick ratio of 6.88.

A number of large investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. lifted its holdings in Galmed Pharmaceuticals by 27.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 21,304 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,555 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Galmed Pharmaceuticals by 36.2% during the 3rd quarter. Geode Capital Management LLC now owns 27,177 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 7,217 shares in the last quarter. Millennium Management LLC acquired a new position in Galmed Pharmaceuticals during the 3rd quarter worth $36,000. Raymond James & Associates lifted its holdings in Galmed Pharmaceuticals by 10.5% during the 3rd quarter. Raymond James & Associates now owns 229,640 shares of the biopharmaceutical company’s stock worth $641,000 after buying an additional 21,775 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in Galmed Pharmaceuticals by 14.3% during the 1st quarter. Morgan Stanley now owns 185,552 shares of the biopharmaceutical company’s stock worth $636,000 after buying an additional 23,200 shares in the last quarter. 13.48% of the stock is currently owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile (Get Rating)

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

Read More

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.